The global hyaluronidase market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing penetration through different applications and incidence of multiple case studies to demonstrate product efficiency.
Applications of hyaluronidase are ophthalmic therapeutic solutions, cosmetic treatments, and cancer therapy. Its developing role in cancer metastasis and therapy due to enzyme based substrates used for noninvasive tumor imaging is projected to propel the demand and subsequent growth of the market with lucrative avenues. The demand of cosmetics and aesthetics procedures is rising with increasing awareness about alteration of physical appearance among people. Due to easy access of advanced cosmetic treatments and growing prevalence of skin disorders the demand of hyaluronidase is rising across cosmetic dermatology.
Hyaluronidase therapy supports in dissolving subcutaneous nodules and correct excessive injected fillers. Due to this interest of professionals has increased in cosmetic industry for gaining knowledge about its adverse effects, use, and applications. In the hyaluronic acid fillers management adoption of enzyme has increased because of all these factors. Though, there are some symptoms of overdose which are sweating, vision, and confusion among others.
Hence, the beautician or practitioner should be skilled and knowledgeable with appropriate dosage of hyaluronidase including information about required remedies and possible complications. Growing advancements focuses on reducing side effects of hyaluronidase administration are anticipated to offer beneficial opportunities to the major market players.
The report on the global hyaluronidase market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Hyaluronidase Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Types (Animal-derived, and Synthetic), Applications (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, and Others) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Amphastar Pharmaceuticals, Inc., PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., and Shreya Life Sciences Pvt. Ltd. |
Market Segment Insights
In terms of types, the hyaluronidase market is segmented into animal-derived and synthetic. The animal-derived segment is expected to hold a key share of the market in the coming years. Various commercial and approved brand are present in the market which are derived from animal sources. Though, due to limitations related to animal-derived products have encouraged the development and usage of synthetic products. The safety and quality of local anesthetic blocks has enhanced by the high efficacy of recombinant human hyaluronidase.
To make sure the correct selection of products, professional must aware about different properties of sources. While recommending therapy Practitioners must analyze the products from confirmed source to make informed decisions. The most widely used animal sources are bovine and porcine products where, synthetic products includes human recombinant sources.
On the basis of applications, the hyaluronidase market is divided into chemotherapy, ophthalmology, plastic surgery, and others. Usage of hyaluronidase is increased majorly in medicine, to augment dispersion and absorption of other injected drugs. Hence, use of hyaluronidase is increased in chemotherapy & osteoarthritis which boosts the generation of revenue. Hence, chemotherapy segment is expected to grow at rapid space over the forecast period.
The growing incidences of hyaluronidase use in dermatology results in largest revenue generation. Establishing a standard protocol is projected to drive the market growth in coming years. Injections are employed in chemotherapy indications. Many case studies and research recommended its use to resolve extravasation. Utility as a complement in chemotherapy is related with improved tumor response to chemotherapeutic drugs.
On the basis of regions, the hyaluronidase market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to occurrence of large number of dermatology clinics prescribing such treatments, presence of major players who manufactures these products, and high acceptance of advanced treatment.
However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to importance of medical tourism for dermatology treatments and chemotherapy applications in several countries. This has encouraged numerous international companies for interments in Asia Pacific. Prevalence of large number of suppliers along with advanced technology in South Korea is driving the growth of the Asian market.
Key players competing in the hyaluronidase market include Amphastar Pharmaceuticals, Inc., PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., and Shreya Life Sciences Pvt. Ltd.
Major market players implement various business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Genetech, Inc., a subsidiary of Roche Holding AG, in February 2019, received FDA approval for its product-Herceptin Hylecta. Herceptin Hylecta is a subcutaneous injection used for treatment of breast cancer patients.
Key players competing in the hyaluronidase market include Amphastar Pharmaceuticals, Inc., PrimaPharma, Inc., Halozyme, Inc., Bausch & Lomb Incorporated, The Cooper Companies Inc., Sun Pharmaceutical Industries Ltd., STEMCELL Technologies Inc., and Shreya Life Sciences Pvt. Ltd.
Major market players implement various business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Genetech, Inc., a subsidiary of Roche Holding AG, in February 2019, received FDA approval for its product-Herceptin Hylecta. Herceptin Hylecta is a subcutaneous injection used for treatment of breast cancer patients.
Some other reports from this category!